Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 15/20 | 0.51 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.41 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16184622 | 0.96 | GBA1 (0.49) | GBA1EHMT2EHMT1MEN1KMT2A | |
| SCHEMBL16184590 | 0.93 | GBA1 (0.51) | GBA1PDE7APDE7BEHMT2EHMT1 | |
| SCHEMBL16184481 | 0.92 | GBA1 (0.56) | GBA1PDE7APDE7BMEN1HSP90AA1 | |
| SCHEMBL16184535 | 0.91 | GBA1 (0.55) | GBA1PDE7APDE7BEHMT2EHMT1 | |
| SCHEMBL16184561 | 0.89 | GBA1 (0.52) | GBA1PDE7APDE7BEHMT2EHMT1 | |
| SCHEMBL16184509 | 0.89 | GBA1 (0.53) | GBA1PDE7APDE7BABCB1ABCG2 | |
| SCHEMBL16184593 | 0.89 | GBA1 (0.49) | GBA1EHMT2EHMT1MEN1KMT2A | |
| SCHEMBL16184646 | 0.89 | GBA1 (0.55) | GBA1PDE7APDE7BEHMT2EHMT1 | |
| SCHEMBL16184675 | 0.88 | GBA1 (0.52) | GBA1PDE7APDE7BEHMT2EHMT1 | |
| SCHEMBL16184484 | 0.88 | GBA1 (0.54) | GBA1MEN1KMT2AABCB1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | GBA1 1316/4885PDE7A 366/4885PDE7B 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.